Molecular pathophysiology of chronic myelogenous leukemia

Hematology and Cell Therapy

Volumn 40, Issue 5, 1998, Pages 217-221

  Turhan, A G ^a   Solary, E ^c   Vainchenker, W ^a   Dusanter Fourt, I ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ICGM Hôpital Cochin ^*  (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; GENE DELETION; HUMAN; LEUKEMOGENESIS; ONCOGENE; PATHOPHYSIOLOGY; PHILADELPHIA 1 CHROMOSOME; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

BONE MARROW TRANSPLANTATION; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; SIGNAL TRANSDUCTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031741577     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T (1994) : Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway, EMBO J 13:764-773
2. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON (1995) : Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell 82:981-988
3. Gishizky ML, Cortez D, Pendergast AM (1995): Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Proc Natl Acad Sci U S A 92:10889-10893
4. Sawyers CL, Callahan W, Witte ON (1992): Dominant negative MYC blocks transformation by ABL oncogenes. Cell 70: 901-910
5. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL (1995) The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 92: 11746-11750
6. Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B (1995) : Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86 :726-736
7. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P,Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B (1997): Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J 16 :6151-6161
8. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) : Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 :231-241
9. Blume-Jensen P, Janknecht R, Hunter T (1998): The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser 136. Curr Biol 8 :779-782
10. Carlesso N, Frank DA, Griffin JD (1996) : Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med 183:811-820
11. Ilaria RL Jr, Van Etten RA (1996): P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 271:31704-31710
12. Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG (1998): BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line. Oncogene 16: 489-496
13. Chai SK, Nichols GL, Rothman P (1997): Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol 159 :4720-4728
14. Danial NN, Pernis A, Rothman PB (1995): Jak-STAT signaling induced by the v-abl oncogene. Science 269 :1875-1877
15. Grimm S, Bauer MK, Baeuerle PA, Schulze-Osthoff K (1996): Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J Cell Biol 134 :13-23
16. Beg AA, Baltimore D (1996): An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 274 :782-784
17. Hamdane M, David-Cordonnier MH, D'Halluin JC (1997): Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 15:2267-2275
18. Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin AS Jr (1998) A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev12 :968-981
19. Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ (1994): Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 269:22925-22928
20. Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, de Jong R, Druker B, Heisterkamp N, Chen LB, et al (1995) : CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem 270 :29145-29150
21. Danhauser-Riedl S, Warmuth M, Druker BJ, Emmerich B, Hallek M (1996): Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells. Cancer Res 56 :3589-3596
22. Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD (1996): The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene 12 :839-846
23. Carpino N, Wisniewski D, Strife A, Marshak D, Kobayashi R, Stillman B, Clarkson B: p62(dok) (1997): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 88:197-204
24. LaMontagne KR Jr, Flint AJ, Franza BR Jr, Pandergast AM, Tonks NK (1998): Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol Cell Biol 18:2965-2975
25. Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM (1998) : Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway. Genes Dev 12:1415-1424
26. Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N (1997): New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 11:1404-1428
27. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF (1987): Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 328 :342-344
28. Verfaillie CM, McCarthy JB, McGlave PB (1992): Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 90 :1232-1241
29. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM (1994): Interferon-alpha restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired beta 1 integrin receptor function. J Clin Invest 94:384-391
30. Bazzoni G, Carlesso N, Griffin JD, Hemler ME (1996): Bcr/Abl expression stimulates integrin function in hematopoietic cell lines. J Clin Invest 98 :521-528
31. Salgia R, Brunkhorst B, Pisick E, Li JL, Lo SH, Chen LB, Griffin JD (1995): Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11:1149-1155
32. Eaves CJ, Eaves AC: Cell culture studies in CML. (1987) Baillieres Clin Haematol 1:931-961
33. Issaad C, Vainchenker W (1994): Growth of erythroid colonies in chronic myelogenous leukemia is independent of erythropoietin only in the presence of steel factor. Blood 84 :3447-3456
34. Spooncer E, Fairbairn L, Cowling GJ, Dexter TM, Whetton AD, Owen-Lynch PJ (1994) Biological consequences of p160v-abl protein tyrosine kinase activity in a primitive, multipotent haemopoietic cell line. Leukemia 8:620-630
35. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG (1994): BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83: 1179-1187
36. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ (1994) : Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 83:2038-2044
37. Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M (1997) : Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leuk Lymphoma 25:121-133
38. Roger R, Issaad C, Pallardy M, Leglise MC, Turhan AG, Bertoglio J, Breard J (1996): BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood 87:1113-1122
39. Cortez D, Stoica G, Pierce JH, Pendergast AM: (1996) The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway. Oncogene 13 :2589-2594
40. Sanchez-Garcia I, Grutz G (1995): Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A 92:5287-5291
41. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E (1998): BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 91:2415-2422